logo Ibionextlogo Ibionext
  • HOME
  • ABOUT US
  • STRATEGY
  • TEAM
  • OUR COMPANIES
  • NEWS & MEDIA
  • CONTACT
  • Français
Twitter
LinkedIn

Prophesee announces strategic investment from leading AI investor Sinovation Ventures to accelerate commercialization of neuromorphic vision sensing platform

July 6, 2021NewsIbionext

Corporate investor Xiaomi and VC Inno-Chip also back company in an agreement led by firm founded by AI expert Dr. Kai-Fu Lee to expand global footprint and strengthen presence in key China market

PARIS, July 6, 2021 – Prophesee, the world’s leading developer of neuromorphic vision solutions, today announced a strategic partnership and investment by leading tech venture capital firm Sinovation Ventures. Prophesee also announced support from new corporate investor Xiaomi, one of the top three mobile device suppliers in the world, and Inno-Chip, an investment firm which has obtained investment and support from Will Semiconductor, owner of OmniVision. They join an already strong group of international investors from North America, Europe and Japan.

The support will be used to accelerate the development and commercialization of Prophesee’s next generation hardware and software products; evolve its product roadmap plans to address new and emerging market opportunities; and expand its operational infrastructure required to further scale the company. Prophesee will also leverage the partnerships to further strengthen its commercial presence and resources in China to address growing customer demand, as well as develop broader relationships across key ecosystems in semiconductors, industrial, robotics, IoT and mobile devices.

The involvement by Sinovation and its founder Dr. Kai-Fu Lee represents a significant endorsement from a notable global expert in AI technology and venture capital. Sinovation is famous for nurturing several successful AI unicorns in its portfolio including Momenta, WeRide, AInnovation, 4Paradigm, Horizon Robotics and more, and has more than $2.5 billion assets under management.

This is the first investment by the fund in a Europe-based company as it primarily invests in the China market.

The support from all three new investors solidifies Prophesee’s presence in the important Chinese market, building on previous investments from Europe, the US and Japan. The strategic involvement of Xiaomi and Inno-Chip, investment firm which has obtained investment and support from Will Semiconductor, holding company of fast-growing and top three global CMOS image sensor supplier OmniVision, provides additional reach into the critical mobile and semiconductor segments.

“This round of funding takes us another step closer to establishing Prophesee as a clear leader in applying neuromorphic methods to machine vision and AI. The commitment from these new partners is a strategic part of our evolution and growth plan that will give us expanded global access to customers, particularly in China, for our revolutionary event-based vision sensing and processing approach,” noted Luca Verre, CEO and founder of Prophesee. “As we continue to develop strategies to align with targeted market segments like mobile, automotive, AR and industrial automation, involvement from established leaders such as Sinovation, Xiaomi and Inno-Chip will complement our current expertise and business networks, and position us strongly in the relevant ecosystems.”

“Sinovation Ventures is committed to finding and backing disruptive pioneers that have the potential to truly shift paradigms in how AI-enabled technology can improve our lives. Prophesee’s technology has great potential in many sectors, such as computational photography, autonomous driving, industrial automation, IoT, Healthcare, AR and VR etc. Computer vision applications are flourishing globally and can benefit from Prophesee’s latest technological breakthrough. I believe Prophesee’s advanced technology in AI and machine vision will open up more possibilities globally to enable new levels of automation, safety and efficiency for many industries.” said Dr. Kai-Fu Lee.

 

ABOUT PROPHESEE

Prophesee is the inventor of the world’s most advanced neuromorphic vision systems.

The company developed a breakthrough Event-Based Vision approach to machine vision. This new vision category allows for significant reductions of power, latency and data processing requirements to reveal what was invisible to traditional frame-based sensors until now. Prophesee’s patented Metavision® sensors and algorithms mimic how the human eye and brain work to dramatically improve efficiency in areas such as autonomous vehicles, industrial automation, IoT, mobile and AR/VR.

Prophesee is based in Paris, with local offices in Grenoble, Shanghai, Tokyo and Silicon Valley. The company is driven by a team of more than 100 visionary engineers, holds more than 50 international patents and is backed by leading international equity and corporate investors including 360 Capital Partners, European Investment Bank, iBionext, Inno-Chip, Intel Capital, Renault Group, Robert Bosch Venture Capital, Sinovation, Supernova Invest, Xiaomi.

 

MEDIA INQUIRIES

Prophesee PR Agency: Mike Sottak / mike@wiredislandpr.com / +1 650 248 9597

Prophesee: Guillaume Butin – Marketing Communications Director – press@prophesee.ai

 

GET IN TOUCH
Previous post Chronolife and Chugai Pharma France to develop a smart textile for the monitoring of joint pathologies Next post Macnica ATD Europe and Prophesee Sign Agreement to Jointly Market Event-Based Vision Technology

SEARCH

ARCHIVES

  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016

CATEGORIES

  • Events (3)
  • News (78)
  • Press releases (67)

LATEST NEWS

  • Théa partners with Tilak Healthcare to promote OdySight: First remote monitoring solution for ophthalmology June 29, 2022
  • GrAI Matter Labs Unveils Life-Ready AI with GrAI VIP at GLOBAL INDUSTRIE May 16, 2022
  • Rigshospitalet, the main hospital in Denmark based in Copenhagen, collaborate with Chronolife for a clinical investigation in Oncology March 31, 2022
  • Europrotect partners with Chronolife for the development and production of a device to measure physiological data, integrated into a firefighter’s intervention suit to limit the risk of thermal stress March 13, 2022
  • OdySight, first remote monitoring solution in ophthalmology to be reimbursed by the Social Security March 9, 2022

CONTACT US

74, rue du Faubourg Saint-Antoine 75012 Paris
+33 1 76 21 47 50
contact@ibionext.com

LEGAL NOTICES

  • Cookies Policy
  • Privacy Policy
  • Terms of use
© 2023 iBionext. All rights reserved